Pharma IQ Glossary: Parenteral Drug (LVP, SVP)
A Parenteral Drug (LVP, SVP) is defined as one intended for injection through the skin or other external boundary tissue, rather than through the alimentary canal, so that active substances they contain are administered, using gravity or force, directly into a blood vessel, organ, tissue, or lesion. They are infused when administered intravenously (IV), or injected when administered intramuscularly (IM), or subcutaneously into the human body. A large volume parenteral (LVP) is a unit dose container of greater than 100ml that is terminally sterilized by heat. Small volume parenteral (SVP) is a "catch-all" for all non-LVP parenterals products except biologicals.
Cancer ‘vaccine’ destroys tumors in recent study
February 06 by Pharma IQ NewsResearchers have managed to eliminate distant cancerous growths in mice by activating T-cells in tumors.
National price list enters into force
January 05 by Chanice HenryNew national price list for medical services went live on the first of January
‘Brexit a major opportunity for UK pharma’
December 05 by Catalyst Corporate FinanceDespite concern expressed by the pharmaceutical industry, Catalyst Corporate Finance argues that the UK’s decision to leave the European Union in fact represents a major opportunity for the country’s...
The Future Of Drug Discovery: AI 2020
November 14 by Pharmaceuticals & Biotechnology EditorDrug development approaches a new era as digitalization introduces sophisticated technologies which can neutralize the costly hazards in pharma’s R&D pipelines, according to our new study
New weapons to fight cancer: Artificial intelligence and cryptography therapy
October 31 by Michael A. PopovMichael A. Popov, Director Researcher at Prime States Quantum Lab applies new strategies to one of the most difficult unsolved problems of modern medicine and molecular genetics – cancer
Biomanufacturing Market Report: Supporting the bioboom
September 20 by Pharma IQThe need for more speed to the market in biomanufacturing is fueling the acceptance and implementation of single use systems despite their complications
5 thoughts for physicians switching patients to biosimilars
August 15 by Chanice HenryIn response to the recent bioboom, physicians may consider switching patients to a biosimilar for a more affordable alternative. However, this is a decision that shouldn’t be made in haste and has a f...
Combination products – A 5 point checklist for compliance approval
July 25 by Chanice HenryAfter a decade in development, products in a multi-billion dollar sector are falling at the last hurdle – under-the-gaze of the regulatorCombination products, or drug and device products, fuse a medic...
